罗米地辛联合CHOP对比CHOP治疗初治外周T细胞淋巴瘤:Ro-CHOP III期研究结果(由LYSA开展)
这项随机III期研究纳入421例初治外周T细胞淋巴瘤成人患者,比较罗米地辛联合CHOP(Ro-CHOP)与单纯CHOP的疗效。中位无进展生存期Ro-CHOP组12.0个月(95%CI 9.0至25.8)对比CHOP组10.2个月(95%CI 7.4至13.2),风险比0.81(P=0.096)。罗米地辛联合CHOP未改善无进展生存期、缓解率或总生存期,且增加了≥3级治疗中出现的不良事件频率。
要点
- Ro-CHOP组中位无进展生存期12.0个月对比CHOP组10.2个月,风险比0.81(P=0.096),未达统计学显著。
- Ro-CHOP组与CHOP组客观缓解率63%对比60%,完全缓解加未确认完全缓解率41%对比37%(所有比较P>0.1)。
- Ro-CHOP组≥3级治疗中出现不良事件包括血小板减少50%对比10%、中性粒细胞减少49%对比33%、贫血47%对比17%、白细胞减少32%对比20%。
核心结论
- 罗米地辛联合CHOP未改善无进展生存期、缓解率或总生存期,且增加了≥3级治疗中出现的不良事件频率。
- Ro-CHOP不代表初治外周T细胞淋巴瘤标准治疗的重大进展。
研究设计与样本
- 随机III期研究,比较Ro-CHOP与CHOP在初治外周T细胞淋巴瘤成人患者中的疗效。
- 所有患者接受CHOP方案,每3周1个周期,共6个周期。
- 罗米地辛12 mg/m2,每3周周期的第1天和第8天经4小时静脉给药,共6个周期。
- 主要终点为根据国际工作组1999标准评估的无进展生存期。
- 2013年1月至2017年12月共入组421例患者(Ro-CHOP组n=211;CHOP组n=210)。
主要发现
- Ro-CHOP组对比CHOP组中位无进展生存期12.0个月(95%CI 9.0至25.8)对比10.2个月(95%CI 7.4至13.2),风险比0.81(P=0.096)。
- Ro-CHOP组对比CHOP组中位总生存期51.8个月对比42.9个月。
- Ro-CHOP组对比CHOP组客观缓解率63%对比60%,完全缓解加未确认完全缓解率41%对比37%(所有比较P>0.1)。
- Ro-CHOP组对比CHOP组≥3级治疗中出现不良事件:血小板减少50%对比10%,中性粒细胞减少49%对比33%,贫血47%对比17%,白细胞减少32%对比20%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Results from a phase Ib and II study showed the feasibility of combining romidepsin with CHOP (Ro-CHOP). METHODS: This study is a randomized phase III study of Ro-CHOP versus CHOP in adult patients with previously untreated PTCL. All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m2, was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. The primary end point was progression-free survival (PFS) according to International Working Group 1999 criteria. RESULTS: Between January 2013 and December 2017, 421 patients were enrolled (Ro-CHOP, n = 211; CHOP, n = 210). The median PFS for Ro-CHOP versus CHOP was 12.0 months (95% CI, 9.0 to 25.8) versus 10.2 months (95% CI, 7.4 to 13.2) with a hazard ratio of 0.81 (P = .096). In the Ro-CHOP versus CHOP arms, the median overall survival was 51.8 versus 42.9 months and the objective response rate was 63% versus 60% with complete response plus unconfirmed complete response rates of 41% versus 37% (P > .1 in all comparisons), respectively. Grade 3 or 4 treatment-emergent adverse events occurring in ≥ 30% of patients in the Ro-CHOP arm included thrombocytopenia (50% v 10% in the Ro-CHOP v CHOP arms, respectively), neutropenia (49% v 33%), anemia (47% v 17%), and leukopenia (32% v 20%). CONCLUSION: The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.
引用
- Bachy E, Camus V, Thieblemont C, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2021. PMID: 34843406. doi:10.1200/JCO.21.01815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。